PMAM
VKTX icon

Picton Mahoney Asset Management’s Viking Therapeutics VKTX Stock Holding History

Picton Mahoney Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-558
Closed -$14K – 1183
2025
Q1 		$14K Buy
+558
New +$17.6K ﹤0.01% 612

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Picton Mahoney Asset Management's VKTX Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 558 shares — an estimated $14K sold.

Picton Mahoney Asset Management first reported a position in VKTX in Q1 2025 and held it in 1 quarter. The position peaked at $14K in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 558 Viking Therapeutics shares in Q2 2025, an estimated $14K.
  • Picton Mahoney Asset Management first reported a position in Viking Therapeutics in Q1 2025 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Viking Therapeutics position peaked at $14K in Q1 2025.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.